History of neuromyelitis optica spectrum disorders, development of the diagnostic critera

Česká verzia

Authors: P. Nytrová
Authors place of work: Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze
Published in the journal: Cesk Slov Neurol N 2020; 83/116(supplementum 1): 5-10
Category:
doi: https://doi.org/10.14735/amcsnn2020S5

Summary

Eugene Devic defined neuromyelitis optica (NMO) as a monophasic syndrome characterized by bilateral optic neuritis and acute myelitis at the end of 19^th century. When we look at the whole 19^th century, prior to the definition of NMO, we can find publications about the coincidence of an impairment of the optic nerves and spinal cord of different etiology than in neurosyphilis. The original Devic’s concept of the monophasic syndrome was adjusted to predominantly relapsing--remitting disorder with clinical manifestation affecting not only optic nerves and the spinal cord, but also the brain stem and other parts of the CNS during 20^th century. In 2007, the diagnostic criteria for NMO spectrum disorders were published for this reason and were updated in 2015. The discovery of antibodies to aquaporin-4 played an important role in all these events. This serological biomarker has been implemented into the diagnostic criteria. Furthermore, these antibodies facilitated differentiation between NMO and MS. The assessment of aquaporin-4 improves the diagnostic procedure of the autoimmune inflammatory disorders of the CNS.

Keywords:

Multiple sclerosis – diagnostic criteria – history – neuromyelitis optica spectrum disorders – MOG encephalomyelitis

Zdroje

1. Wingerchuk DM, Lennon VA, Lucchinetti CF et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6 (9): 805–815. doi: 10.1016/S1474-4422 (07) 70216-8.

2. Wingerchuk D, Banwell B, Bennett JL et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85 (2): 177–189. doi: 10.1212/WNL.0000000000001729.

3. Jarius S, Wildemann B. The history of neuromyelitis optica. Part 2: ‚Spinal amaurosis‘, or how it all began. J Neuroinflammation 2019; 16 (1): 280. doi: 10.1186/s12974-019-1594-1.

4. Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 (9451): 2106–2112. doi: 10.1016/S0140-6736 (04) 17551-X.

5. Lennon VA, Kryzer TJ, Pittock SJ et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202 (4): 473–477. doi: 10.1084/jem.20050304.

6. Waters PJ, Pittock SJ, Bennett JL et al. Evaluation of aquaporin-4 antibody assays. Clin Exp Neuroimmunol 2014; 5 (3): 290–303. doi: 10.1111/cen3.12107.

7. Mader S, Gredler V, Schanda K et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184. doi: 10.1186/1742-2094-8-184.

8. Kitley J, Woodhall M, Waters P et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012; 79 (12): 1273–1277. doi: 10.1212/WNL.0b013e31826aac4e.

9. Fujihara K. Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 2019; 32 (3): 385–394. doi: 10.1097/WCO.0000000000000694.

10. Weber MS, Derfuss T, Metz I et al. Defining distinct features of anti-MOG antibody associated central nervous system demyelination. Ther Adv Neurol Disord 2018; 11: 1756286418762083. doi: 10.1177/1756286418762083. eCollection 2018.

11. Devic E. Myélite aiguë dorso-lombaire avec névrite optique – Autopsie. In: Congrès français de médecine (Premiere Session; Lyon, 1894; procès-verbaux, mémoires et discussions; publiés par M. le Dr L. Bard). Paris: Lyon: Asselin et Houzeau, Louis Savy 1895: 434–439.

12. Gault F. De la neuromyélite optique aiguë. Thése: Faculté de Médecine et de Pharmacie 1894.

13. Sichel J. Traité de l‘ophthalmie, la cataracte et l‘amaurose. Paris, Montpellier, Lyon, Londres, Strasbourg: Germer Baillière 1837.

14. Carron du Villards CJF. Lettre de M. Carron du Villards à M. Pétrequin Annales d‘Oculistique et Gynécologie 1838; 1: 87–90.

15. Pétrequin JE. Nouveau traité de l‘amaurose ou goutte-sereine, considérée au point de vue clinique, avec des recherches nouvelles sur le méthodes spéciales de traitement qui conviennent a ses différentes espèces. In: Annales de la Société de Sciences Naturelles, de Bruges, année 1840–1841; 41. Bruge: Société de Sciences Naturelles 1840: 241–372.

16. Pétrequin JE. Nouvelles recherches sur l‘action thérapeutique de la noix vomique et de ses préparations dans les affections paralytiques. Gazette Medicale de Paris 1838; 6: 676–682.

17. Chelius MJ. Handbuch der Augenheilkunde. E. Schweizerbart‘sche Verlagsbuchhandlung 1843.

18. Hocken EO. Illustrations on the pathology and treatment of amaurosis. Part IV. Amaurosis from affections of the spinal cord or its membranes. Lancet 1841; 36: 470–474.

19. Jarius S, WildemannJ B. ‘Spinal amaurosis’ (1841). On the early contribution of Edward Hocken to the concept of neuromyelitis optica. Neurol 2014; 261: 400–404.

20. Ruete CGT. Lehrbuch der Ophthalmologie für Aerzte und Studierende. 1st ed. Braunschweig: F. Vieweg und Sohn 1845.

21. Jarius S, Wildemann B. The case of the Marquis de Causan (1804): an early account of visual loss associated with spinal cord inflammation. J Neurol 2012; 259 (7): 1354–1357. doi: 10.1007/s00415-011-6355-8.

22. Allbutt TC. On the ophthalmoscopic signs of spinal disease. Lancet 1870; 95: 76–78.

23. Brain WR. Critical review: disseminated sclerosis. QJM 1930; 23: 343–391.

24. Wingerchuk D, Hogancamp W, OBrien P et al. The clinical course of neuromyelitis optica (Devic‘s syndrome). Neurology 1999; 53 (5): 1107–1114. doi: 10.1212/WNL. 53.5.1107.

25. Wingerchuk DM, Lennon VA, Pittock SJ et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10): 1485–1489.

26. Hartung HP, Graf J, Aktas O et al. Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change. Current Opinion in Neurology 2019; 32 (3): 327–337. doi: 10.1097/WCO.0000000000000699.

27. Kuhle J, Lindberg RL, Regeniter A et al. Antimyelin antibodies in clinically isolated syndromes correlate with inflammation in MRI and CSF. J Neurol 2007; 254 (2): 160–168. doi: 10.1007/s00415-006-0299-4.

28. Jarius S, Paul F, Aktas O, at al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Neuroinflammation 2018; 15 (1): 134. doi: 10.1186/s12974-018-1144-2.

29. Reindl M, Schanda K, Woodhall M et al. International multicenter examination of MOG antibody assays. Neurol Neuroimmunol Neuroinflamm 2020; 7 (2). pii: e674. doi: 10.1212/NXI.0000000000000674.

30. Jarius S, Ruprecht K, Stellmann JP et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflammation. 2018; 15 (1): 88. doi: 10.1186/s12974-018-1108-6.

31. Doutlík S, Šíblová O, Kryl R et al. Neuromyelitis optica jako parainfekční komplikace planých neštovic. Cesk Slov Neurol N 1975; 4: 238–242.

32. Jarius S, Ruprecht K, Kleiter I et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13 (1): 280. doi: 10.1186/s12974-016-0718-0.